One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 185,000 shares of Swiss multinational health care company Roche on Friday, as the share price of the fund traded up over 1% in the day’s session. Its share price has greatly improved over the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) sold 189,500 over-the-counter shares of Roche. At Friday’s closing price, this would have valued this sale at roughly $9.5 million. This is only a small fraction of the total holdings. This fund is up 29% over the past 52 weeks.
Here is a quick look at all the other sales that took place across all ARK ETFs:
| Fund | Ticker | Company Name | Shares Traded |
|---|---|---|---|
| ARKF | 1833HK | Ping An Good Doctor | 1,951,500 |
| ARKG | PSTI | Pluristem Therapeutics | 4,301 |
| ARKG | CDNA | CareDx | 73,873 |
| ARKG | RHHBY | Roche | 189,500 |
| ARKK | PRLB | Proto Labs | 17,225 |
| ARKK | SQ | Square | 43,266 |
| ARKK | SE | Sea | 66,115 |
| ARKQ | XONE | Exone | 91,224 |
| ARKQ | BIDU | Baidu | 84,975 |
| ARKW | MELI | Mercado | 5,185 |
| ARKW | SQ | Square | 36,059 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
